Key highlights
13 June 2023 – 1 mins read
LinkedIn
Twitter
Facebook
U.S. FDA approves Bylvay® for patients living with cholestatic pruritus due to Alagille syndrome
PARIS, FRANCE, 13 June 2023 – Ipsen (Euronext: IPN: ADR: IPSEY) today announced that the U.S. Food and Drug Administration (FDA) has approved Bylvay® (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille…
27 April 2023 – 1 mins read
Ipsen delivers robust sales growth in the first quarter of 2023 and confirms its full-year guidance
Paris (France), 27 April 2023
Explore more press releases
Filter
Topics
Period
Filter by
recent search
Showing: 1 – 05 of 227 Press Releases
–
04 September 2024
04 September 2024
Ipsen – August 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital
–
13 August 2024
13 August 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 32 – 2024
Aggregated presentation by day and by market
–
06 August 2024
06 August 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 31 – 2024
Aggregated presentation by day and by market
–
05 August 2024
05 August 2024
Ipsen – July 2024 – Monthly information relative to the total number of voting rights and shares composing the share capital
Monthly information relative to the total number of voting rights and shares composing the share capital
–
30 July 2024
30 July 2024
IPSEN – Buy-back programme – Art 5 of MAR – Week 30 – 2024
Aggregated presentation by day and by market
Your dedicated contacts
-
Amy Wolf
Vice President, Corporate Brand Strategy and Communications
-
-
Ioana Piscociu
Senior Manager, Media Relations
-
Related links